Press Releases
// Jan 08, 2024
ElevateBio to Highlight Growth of its Genetic Medicine Business Driven By Gene Editing and Manufacturing Partnerships at the 42nd Annual J.P. Morgan Healthcare Conference
// Sep 26, 2023
Kyverna Therapeutics and ElevateBio to Advance Kyverna’s Ingenui-T Cell Therapy Manufacturing
// May 24, 2023
ElevateBio Announces $401 Million Series D Financing to Further Accelerate Growth
// May 24, 2023
Novo Nordisk and Life Edit Therapeutics Establish Multi-Target Collaboration to Discover and Develop Gene Editing Therapies for Rare and Cardiometabolic Diseases
// May 15, 2023
ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting Highlighting Optimization of Processes for Viral Vector Production
// Apr 25, 2023
Life Edit Therapeutics to Present Data Demonstrating Therapeutic Potential of its Novel Gene Editing Platform
// Mar 07, 2023
ElevateBio Appoints Heidi L. Wagner, J.D., as Global Head of Government Affairs
// Feb 22, 2023
Moderna and Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies
// Jan 05, 2023
ElevateBio to Present at the 41st Annual J.P. Morgan Healthcare Conference
// Nov 15, 2022
ElevateBio and Affini-T Therapeutics Announce Partnership to Advance Affini-T’s T Cell Therapy Programs Targeting Core Oncogenic Drivers
// Aug 25, 2022
